Cipher Pharmaceuticals Inc  

(Public, TSE:DND)   Watch this stock  
Find more results for Shawn G. Ross
-0.24 (-1.67%)
Oct 31 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 13.64 - 15.78
52 week 6.76 - 15.78
Open 14.79
Vol / Avg. 458,486.00/97,763.00
Mkt cap 362.50M
P/E 13.51
Div/yield     -
EPS 1.05
Shares 25.64M
Beta -1.65
Inst. own     -
Sep 9, 2014
Cipher Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 51.57% 92.43%
Operating margin 66.56% 67.22%
EBITD margin - 71.39%
Return on average assets 31.04% 64.43%
Return on average equity 39.33% 97.60%
Employees 13 -
CDP Score - -


Unit 16, 5650 Tomken Rd.
+1-905-6025840 (Phone)
+1-905-6020628 (Fax)

Website links


Cipher Pharmaceuticals Inc. (Cipher) is a specialty commercial stage pharmaceutical company focused on the development and commercialization of formulations of marketed molecules. It develops formulations of marketed drugs using third party drug delivery technologies. Its CIP-FENOFIBRATE is a formulation of the active ingredient fenofibrate, which is used in the treatment of Hyperlipidemia. Its CIP-TRAMADOL ER is a sustained-release formulation of the active ingredient tramadol, which is used for the management of moderate to moderately severe pain. CIP-ISOTRETINOIN is based on the Lidose delivery system and was in-licensed from Galephar Pharmaceutical Research, Inc. (Galephar). Its marketing rights to CIPISOTRETINOIN include the Americas and the Pacific Rim. During the year ended December 31, 2012, Cipher obtained exclusive license and distribution rights in Canada to market the Betesil Patch, a self-adhesive medicated plaster for the treatment of inflammatory skin conditions.

Officers and directors

Gerald P. McDole Independent Chairman of the Board
Age: 74
Larry Andrews President, Director, IR Contact Officer
Shawn Patrick O'Brien Chief Executive Officer
Norman C. Evans Chief Financial Officer, Secretary
Joan Chypyha Vice President - Marketing and Sales, Director of Sales, Director of Marketing
Jason A. Gross Pharm.D. Vice President - Scientific Affairs
Stefan Aigner M.D. Independent Director
William D. Claypool M.D. Independent Director
Age: 61
John D. Mull M.D. Independent Director
Thomas G. Wellner Independent Director